Table 7.
Studies Using Mitotane as a Therapeutic Agent (Nonadjuvant)
| Study | Year | Design | Number of Patients | Observed Responses | Number of Responders | Percent |
|---|---|---|---|---|---|---|
| Van Slooten (371) | 1984 | Retrospective | 34 | PR | 8 | 23.53 |
| Venkatesh (26) | 1989 | Retrospective | 64 | PR | 21 | 32.81 |
| Luton (10) | 1990 | Retrospective | 37 | SD (2), PR (8) | 10 | 27.03 |
| Decker (372) | 1991 | Prospective | 36 | CR (2), PR (6) | 8 | 22.22 |
| Pommier (275) | 1992 | Retrospective | 29 | PR (7) | 7 | 24.14 |
| Haak (269) | 1994 | Retrospective | 52 | PR (7), CR (8) | 15 | 28.85 |
| Barzon (370) | 1997 | Retrospective | 11 | PR (2) | 2 | 18.18 |
| Williamson (373) | 2000 | Prospective | 16 | SD (2), PR (2) | 4 | 25.00 |
| Baudin (374) | 2001 | Prospective | 13 | CR (1), PR (3) | 4 | 30.77 |
| Gonzalez (244) | 2007 | Retrospective | 67 | CR (4), SD (10), PR (9) | 23 | 34.33 |
| Total | 359 | 102 | 28.41 | |||
| Average % | 26.01 |
Abbreviations: PR, partial remission; SD, stable disease; CR, complete remission.